Source: Annual Congress 2007 - Pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
S. McKenna, D. Meads, N. Doughty, J. Pepke-Zaba (Manchester, Cambridge, United Kingdom). Responsiveness of cambridge pulmonary hypertension outcome review (CAMPHOR) scores and utility in pulmonary hypertension (PH) patients. Eur Respir J 2007; 30: Suppl. 51, 2077

Member's Comments

No comment yet.

Related content which might interest you: Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 The CAMbridge pulmonary hypertension outcome review (CAMPHOR): development and validation Source: Eur Respir J 2004; 24: Suppl. 48, 111s Year: 2004 An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 56 (4) 1902096; 10.1183/13993003.02096-2019 Year: 2020 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 HRQoL in adult patients with Eisenmenger syndrome (ES) compared to patients with primary pulmonary hypertension (PPH) or post-embolic pulmonary hypertension (PEPH) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002 Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Physical activity (PA) in pulmonary arterial hypertension (PAH) can be predicted by questionnaire Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD): Preliminary data of a longitudinal survey Source: International Congress 2014 – Clinical presentations Year: 2014 Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Psychometric validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015